We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Cancer Research

Cancer Research

Touchlight

At Touchlight we have developed a novel, synthetic DNA vector (dbDNA™) and enzymatic manufacturing process, which enables us to produce DNA at unprecedented speed, scale and purity. Using our patented enzymatic DNA production platform, we are supporting partners that are advancing genetic medicine.

Latest Content

Double helix structure of DNA.

Touchlight and GSK Sign License Agreement for Use of Enzymatic dbDNA Production Technology for mRNA Manufacturing

Touchlight, announced a license agreement with GSK. This agreement grants GSK non-exclusive rights to use Touchlight’s proprietary enzymatic dbDNA™ (doggybone DNA™) technology for the development and production of mRNA-based products.

Cells.

Touchlight, Cell and Gene Therapy Catapult and Complement Therapeutics To Develop Innovative Manufacturing Process for Gene Therapies

The Cell and Gene Therapy Catapult (CGT Catapult), Touchlight, announce that they have been awarded over £1 million in a grant from Innovate UK, as part of the ‘Innovative Technologies: Nucleic Acid Medicines Manufacture’ competition.

Double helix structure of DNA.

University of Liverpool To Use Touchlight’s Rapid Enzymatic dbDNA in Fully Personalised Neoantigen Cancer Vaccine Clinical

The UK’s Medical Research Council is funding a 10-patient Phase I study to deliver rapid personalised treatment for lung cancer patients.

Advertisement

Advertisement

Decoratvive background images

Never miss a story

with the Breaking Science News daily newsletter